50,000 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Oak Harvest Investment Services

Oak Harvest Investment Services acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 50,000 shares of the company’s stock, valued at approximately $1,010,000.

Several other hedge funds have also recently modified their holdings of the stock. Lansforsakringar Fondforvaltning AB publ grew its stake in Teva Pharmaceutical Industries by 2.2% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 250,106 shares of the company’s stock valued at $3,844,000 after acquiring an additional 5,344 shares in the last quarter. Trexquant Investment LP grew its position in shares of Teva Pharmaceutical Industries by 114.8% during the first quarter. Trexquant Investment LP now owns 203,909 shares of the company’s stock valued at $3,134,000 after purchasing an additional 108,986 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Teva Pharmaceutical Industries by 109.2% during the first quarter. Canada Pension Plan Investment Board now owns 150,638 shares of the company’s stock valued at $2,315,000 after purchasing an additional 78,638 shares in the last quarter. Retirement Planning Co of New England Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 97.2% in the first quarter. Retirement Planning Co of New England Inc. now owns 31,228 shares of the company’s stock worth $480,000 after purchasing an additional 15,393 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Teva Pharmaceutical Industries by 0.4% in the first quarter. Royal Bank of Canada now owns 1,181,964 shares of the company’s stock worth $18,167,000 after buying an additional 4,361 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $31.58 on Tuesday. The firm has a market capitalization of $36.22 billion, a PE ratio of 52.63, a price-to-earnings-growth ratio of 1.90 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $31.99. The firm has a 50-day moving average price of $25.87 and a 200-day moving average price of $20.67. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TEVA shares. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, December 22nd. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $32.88.

Insider Activity

In related news, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. This trade represents a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 622,060 shares of company stock worth $17,076,965 in the last ninety days. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.